Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Miriam Heinig"'
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Program sensitivity is a key quality indicator for mammography screening programs (MSP). Estimating program sensitivity usually requires a linkage of screening and cancer registry data. For the German MSP, such data linkage-based
Externí odkaz:
https://doaj.org/article/aa1fa7fedbf3492ebdf3a8afe4608588
Publikováno v:
BMC Public Health, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background In Germany, all women aged 50–69 have been invited to biennial mammography screening since 2009. We aimed to assess longitudinal adherence over ten years in women aged 50 in 2009 and characterize the different adherence groups.
Externí odkaz:
https://doaj.org/article/08a8993f95e44e7e8233bccb77aa74b8
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-12 (2022)
Abstract Background We aimed to explore the potential of German claims data for describing initial and long-term treatment patterns of breast cancer patients undergoing surgery. Methods Using the German Pharmacoepidemiological Research Database (GePa
Externí odkaz:
https://doaj.org/article/6ddc4ae2cdbc456384ab7fe53e47415a
Autor:
Malte Braitmaier, Bianca Kollhorst, Miriam Heinig, Ingo Langner, Jonas Czwikla, Franziska Heinze, Laura Buschmann, Heike Minnerup, Xabiér García-Albéniz, Hans-Werner Hense, André Karch, Hajo Zeeb, Ulrike Haug, Vanessa Didelez
Publikováno v:
Clinical epidemiology, 14:1293-1303
Malte Braitmaier,1 Bianca Kollhorst,1 Miriam Heinig,2 Ingo Langner,2 Jonas Czwikla,3 Franziska Heinze,3 Laura Buschmann,4 Heike Minnerup,4 Xabiér GarcÃa-Albéniz,5,6 Hans-Werner Hense,4 André Karch,4 Hajo Zeeb,7,8 Ulrike Haug,2,8 Vanessa D
Publikováno v:
Future oncology, 17(18):2305-2313
Aims: Premarketing clinical trials are typically conducted under controlled conditions and in selected study populations, so real-world information on the utilization of new cancer drugs is limited. We aimed to explore the potential of German claims
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69b96a8f3b4e69393ee3dac0500640ec
https://www.futuremedicine.com/doi/suppl/10.2217/fon-2020-1052
https://www.futuremedicine.com/doi/suppl/10.2217/fon-2020-1052
Publikováno v:
Pharmacoepidemiology and drug safety, 30(4):462-471
BACKGROUND: Prescribing of menopausal hormone therapy (MHT) declined drastically after publication of the Women's Health Initiative's (WHI) findings in 2002, but studies on longer-term trends and details of use are scarce. METHODS: We used the German
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31efc65c4a703f819defb0b442eae8ea
Wiley Online Library
Wiley Online Library